Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Phase 2
30
about 3 years
15+
2 sites in CA, NY
About this study
This trial is testing if rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) is beneficial for people with high-risk B-cell PTLD during their second phase of treatment. It's also evaluating the use of circulating tumor DNA (ctDNA), a blood test that may help guide treatment decisions in lymphoma patients, to see if it can be used to personalize treatment and reduce side effects without losing effectiveness.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cyclophosphamide
- 2.Take Doxorubicin
- 3.Take Etoposide
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), etoposide, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, injection, intravenous, oral
Primary: Number of participants with Complete Response (CR) rate of 60% or higher
Secondary: Duration of Overall Response (OR), Event Free Survival rate, Progression-Free Survival (PFS) rate
Oncology